1. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation 
Julie Charles, MD, PhD, Jean-Claude Beani, MD, Giacomo Fiandrino, MD, Benoit Busser, PharmD, PhD 
Journal of the American Academy of Dermatology 
Volume 71, Issue 3, Pages e97-e99 (September 2014)
DOI: /j.jaad
Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Langerhans cell histiocytosis and vemurafenib response. Inframammary folds (upper images) and left groin area (lower images) before and after a 6-months period of vemurafenib treatment.
Journal of the American Academy of Dermatology  , e97-e99DOI: ( /j.jaad )
Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Histologic and immunohistologic pictures of Langerhans cell histiocytosis. A, Histologically, tumor cells were medium-sized, with grooved or indented nuclei and abundant eosinophilic cytoplasms. Moderate cellular pleomorphism was also a feature. Mitoses were not exceptional, with absence of overtly atypical forms. B, Low-power view of the biopsy specimen before treatment. C, Tumor cells were uniformly stained by the CD1a antibody, which also highlighted epidermotropic tumor cells. D, After 3 weeks of vemurafenib treatment, the dermal infiltrate had entirely disappeared, being replaced by mixed inflammatory cells. E, After treatment, immunostaining for CD1a was restricted to skin-resident Langerhans cells. (A, B, and D, Hematoxylin-eosin stain; original magnifications: A, ×40; B, ×2.5; D, ×2.5. C and E, SABC; original magnifications: C, ×10; E, ×5.)
Journal of the American Academy of Dermatology  , e97-e99DOI: ( /j.jaad )
Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions